Hyperpigmentation of the face following adalimumab treatment.
Blomberg
Maria
M
Zachariae
Claus O C
CO
Grønhøj
Frederik
F
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D005145:Face; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012880:Skin Pigmentation / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000068879:Adalimumab